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S_nary Four cell lines, the mouse L1210 leukaemia, the human W1L2 lymphoblastoid and two human
ovarian (CHI and 41M) cell lines, were made resistant to ZD1694 (Tomudex) by continual exposure to
incremental doses of the drug. A 500-fold increase in thymidylate synthase (TS) activity is the primary
mechanism of resistance to ZD1694 in the W1L2:RDI" cell line, which is consequently highly cross-resistant
to other folate-based TS inhibitors, including BW1843U89, LY231514 and AG337, but sensitive to antifolates
with other enzyme targets. The CHI:RDI6% cell line is 14-fold resistant to ZD1694, largely accounted for by
the 4.2-fold increase in TS activity. Cross-resistance was observed to other TS inhibitors, including 5-
fluorodeoxyuridine (FdUrd). 41M:RDI6% cells, when exposed to 0.1 #M [3H]ZD1694, accumulated -20-fold
less 3H-labelled material over 24 h than the parental line. Data are consistent with this being the result of
impaired transport of the drug via the reduced folate/methotrexate carrier. Resistance was therefore observed
to methotrexate but not to CB3717, a compound known to use this transport mechanism poorly. The mouse
Ll210:RDl14 cell line does not accumulate ZD1694 or Methotrexate (MTX) polyglutamates. Folylpoly-
glutamate synthetase substrate activity (using ZD1694 as the substrate) was decreased to .13% of that
observed in the parental line. Cross-resistance was found to those compounds known to be active through
polyglutamation.
Keywords ZD1694; thymidylate synthase; drug resistance; polyglutamation; reduced folate carrier; folylpoly-
glutamate synthetase
N4N43,4-dihydro-2-methyl-4-oxoquinazolin-6ylmethyl)-N-
methylamino}2-thenoyl)-L-glutamic acid (ZD1694; Tomudex)
is a potent thymidylate synthase (TS; EC 2.1.1.45) inhibitor
(Jackman et al., 1991a,b; Marsham et al., 1991) which has
successfully completed European phase I (Clarke et al., 1994)
and phase II clinical studies (Burris et al., 1994; Gore et al.,
1994; Smith et al., 1994; Zalcberg et al., 1994). ZD1694 was
designed as a non-nephrotoxcic, highly potent analogue of
N'0-propargyl-5,8-dideazafolic acid (CB3717; Jones et al.,
1981) which was active in phase I/II studies, particularly in
breast tumours, hepatomas and platinum-refractory ovanan
cancer (Calvert et al., 1986; Clarke et al., 1993). CB3717 was
withdrawn from further study because of dose-limiting
nephrotoxicity, a feature overcome, in mouse models, by the
synthesis of more water-soluble analogues (Jones et al., 1989;
Hughes et al., 1990; Jackman et al., 1990, 1991c, Marsham et
al., 1991). Many of these new compounds showed improved
substrate activity for the reduced folate/methotrexate cell
membrane transport carrier protein (RFC) and folylpoly-
glutamate synthetase (FPGS), rendering them potent as cyto-
toxic agents (Jackman et al., 1991d). Polyglutamates of
ZD1694 rapidly accumulate within the cell and studies have
confirmed these to be the cytotoxic species (Jackman et al.,
1991a, 1993a, Ward et al., 1992; Gibson et al., 1993). For
example, a major metabolite, the tetraglutamate, is a 60-fold
better TS inhibitor (K = 1 nM) than the parent drug and is
not readily effluxed from cells. In combination, these pro-
perties explain why ZD1694, although a 20-fold poorer
inhibitor of isolated TS, is 500-fold more cytotoxic than
CB3717.
The pyrrolopyrimidine, LY231514, is another TS inhibitor
currently in phase I clinical study and shares many of the
properties of ZD1694 (Grindey et al., 1992), whereas
BW1843U89, a benzoquinazoline, is unusual in that it has
supenor affinity for the human than for the murine RFC and
cannot be metabolised by FPGS beyond the diglutamate
(Duch et al., 1993). The interaction of such folate-based TS
inhibitors with the RFC and FPGS provides an opportunity
for the design of novel agents that are not substrates for one,
or both, of these proteins. Such compounds may express a
different anti-tumour or toxicity profile. Intrinsic or acquired
resistance due to reduced levels or altered expression of the
RFC or FPGS would be expected to be overcome by such
compounds. AG337 is such an example. It is a lipophilic TS
inhibitor (in phase I study) which is believed to diffuse into
cells and is structurally precluded from polyglutamation
(Webber et al., 1993). Our own studies have identified a
series of highly lipophilic benzylamide analogues of 2-des-
amino-2-methyl-N'0-propargyl-5,8-dideazafolic acid (ICI
198583) with good in vitro activity (Barker et al., 1991;
Skelton et al., 1994). However, we have realised greater in
vivo activity in mice with water-soluble compounds that use
the RFC for cell entry but which are not substrates for
FPGS. Structural modifications of ICI 198583 which produce
this profile include methylation of the 7-position of the
quinazoline ring (Boyle et al., 1993) and the replacement of
glutamate with either natural or unnatural amino acids
(Barker et al., 1991, and manuscript in preparation) or dipep-
tides (Bavetsias et al., 1993; Jackman et al., 1993b).
To aid the understanding of potential resistance mechan-
isms to ZD1694 that may occur in man. and the development
of TS inhibitors that may overcome such resistance, requires
the establishment of a panel of in vitro tumour cell lines with
defined resistance mechanisms. Four cell lines, the L1210
mouse leukaemia, the W1L2 human lymphoblastoid and two
human ovarian (CHI and 41M) cell lines, were exposed to
increasing concentrations of ZD1694 until they were esta-
blished in 1-5Mm of the drug. A range of techniques was
used to define the resistance mechanism(s) in each cell line.
These included measurement of TS enzyme activity and pro-
tein levels, ITP and dUMP concentrations, uptake and poly-
glutamation of the drug, and cross-resistance studies to
antifolates with known mechanisms of action. Two of the
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lines (CHI and W1L2) expressed elevated TS activity, 4- and
500-fold respectively. Resistance in the 41M cells was
accounted for by an impaired reduced folate carrier and in
the L1210 cells by a reduced ability to accumulate ZD1694
polyglutamates.
Materials and methods
Development ofresistance to ZD1694
L1210 (mouse leukaemia) and WlL2 (human lymphoblas-
toid) cells were grown by suspension culture in RPMI-1640
(20 mM HEPES) supplemented with 2 mM L-glutamine, 10%
donor horse serum (Ll210) or fetal calf serum (WIL2) (ICN
Flow, Thame, Oxfordshire, or Imperial Laboratories, And-
over, UK) 20jggml ' gentamycin and 0.5 tgml-' ampho-
tericin as previously described (Jackman et al., 1990). The
human ovarian CHl and 41M (Hills et al., 1989) cell lines
were grown as monolayers in Dulbecco's modified Eagle
medium containing 2 mM glutamine, 10% fetal calf serum
(Imperial Laboratories), 50Mgml-' gentamycin, 2.5 Mg ml-'
amphotericin B, lOigmlV1 insulin, and 0.5#ggml'- hydro-
cortisone in 10% carbon dioxide/90% air. Cells were exposed
initially to an IC50 concentration of ZD1694 until they had
adapted and grew normally (-2 weeks). This was repeated in
doubling doses until the cells were growing normally in 1 JiM
(CHI), 2MM (41M) or 5gM (L1210 and W1L2) ZD1694. The
41M:RDl"' ovarian cell line was successfully cloned to pro-
duce a monoclonal cell line by dilution of a cell suspension to
- 1 cell ml' and plating 200 1l per well of a 96-well micro-
titre plate. The CHl:RDl' cell line was not cloned. Resistant
ovarian cell lines were banked in liquid nitrogen without
drug. Once removed from liquid nitrogen they were subcul-
tured without drug for no more than 4 weeks. The L1210:
RDl" and WlL2:RD"' cell lines were cloned by dilution of
the cell number to 100 and 1 cellsml' respectively and
grown in 2 ml of sloppy agar (0.2%) (L1210) or 200gl of
medium in microtitre plates (W1L2). Once these monoclonal
cell lines were established they were subcultured (and bank-
ed) in medium containing 5 iM ZD1694 and then grown
without drug for 2 weeks before experiments. Resistance to
ZD1694 was not stable for the W1L2 cells and was lost
between 3 and 5 months in drug-free medium. The L1210:
RDl'6 cells maintained their resistance to ZD1694 for at least
1 year. Doubling times for the cells lines were L1210
(-12 h), L1210:RD16" (- 14 h), W1IL2 (-18 h), WIL2:R"'6
(-20h), CH1I (- 18h), CH1:RDl6 (- 18h), 41M (-28h)
and 41M:RD" (-28h).
TS activity, TS enzyme-linkedimmunosorbent assay and
FPGS
TS activity was measured by 3H release as described
previously (Jackman et al., 1986). For the measurement of
CHI ovarian tumour TS kinetic parameters, enzyme was
partially purified and assayed as previously described (Jack-
man et al., 1990). The use of mixed diastereoisomers of
5,1O-methylene tetrahydrofolate 15,10-CH2FH4(6R,S)J rather
than the pure 6R does not affect the analysis, although the
K. values are twice the 6R value (Ward et al., 1992). The
values of the kinetic parameters, K and K., which are the
dissociation constants for I from IE (TS.dUMP.I) and IES
(TS.dUMP.5,lOCH2FH4.I) complexes, respectively, were
determined for ZD1694 and its triglutamate by multivariate
non-linear regression in which measured velocities were fitted
to different rate equations (Ward et al., 1992). TS protein
was estimated by enzyme-liiked immunosorbent assay
(ELISA) using a TS antibody (Aherne et al., 1992). Pure
human TS standard was kindly provided by R Ferone (Well-
come Laboratories, Research Triangle Park, NC, USA).
Dihydrofolate reductase (DHFR) activity was assayed by a
spectrophotometric assay (Jackman et al., 1986). FPGS
assays were performed on crude cytosolic extracts as des-
cribed by Jansen et al. (1990).
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ZD1694 and MTX transport studies
[5-3H]ZD1694 (sp. act. 10Cimmol'1) was synthesised by
Zeneca Cambridge Research Biochemicals (Billingham, UK)
and purified for use as described previously (Gibson et al.,
1993). [3',5',7-3H(N)]MTX sodium salt was purchased from
Moravek Radiochemicals (Brea, CA, USA) at a sp. act. of
15-30Cimmol '. L1210 cells at - 3-3-5 x 105ml' were
resuspended in unsupplemented RPMI or transport buffer, at
a concentration of 2-4 x 106ml1. Transport buffer con-
sisted of 107 mM sodium chloride, 20mM HEPES, 26.2 mM
sodium bicarbonate, 5.3 mM potassium chloride, 1.9 mM cal-
cium chloride, 1 mM magnesium chlonrde, and 7 mM D-
glucose, adjusted to pH 7.4 with sodium hydroxide (Jansen et
al., 1990). After incubation with 0.1 AM _5-3H]ZD1694 (sp.
act. = 10 Ci mol') or 0.5JAM MTX (sp. act. = 2.5 Ci
mmol-'), at 3TC for various times, 1 ml of the cell suspen-
sion was immediately added to 10 ml of ice-cold phosphate-
buffered saline (PBS) or transport buffer and spun at 500g for 5 min. The cells were resuspended in PBS or transport
buffer, spun and then washed again. The final cell pellet was
digested with 0.5ml of 1 M sodium hydroxide, neutralised
with hydrochloric acid and added to 10 ml of Ultima Gold
Scintillant (Canberra Packard, Pangbourne, UK) and the
radioactivity estimated by liquid scintillation counting.
Kinetic parameters for MTX (Kt and V.) were obtained by varying the MTX concentration (0.5-8 gM) in a 5mi
incubation. Values were obtained by fitting the data to the
Michaelis-Menten equation [v = (V. x S)/(S + KJ) by
non-linear least-squares analysis (Jennrich et al., 1968). Inhibition of 3H MTX transport by ZD1694 was performed
at 5 min (0.5 iM MT) using a range of ZD1694 concentra-
tions (0.5-8pM). Data were fitted to the competitive inhibi-
tion equation [v = (V. x S)/S x Km (1 + I/K)] by non-linear
least-squares analysis and values for K, obtained. Since 41M
cells are adherent to plastic, a different assay procedure was
employed. Cells were grown in T25 Nunc tissue culture flasks
(Gibco BRL, Paisley, UK) for several days until they reached
a concentration of -3 x 106 cells (not confluent). The medium
was decanted, and 2 ml of unsupplemented Dulbecco's
modified Eagle medium containing 0.1 JAM [3H]ZD1694 was
added followed by incubation at 37C by floating the flasks
on a water bath for the times indicated. The cells were
washed twice with 50 ml of ice-cold PBS, digested with
sodium hydroxide and counted as described above.
Measurement ofZD1694, ICI 198583 and MTX uptake and
polyglutamation
The method for analysing ZD1694 polyglutamates using an
ion-pair high-performance liquid chromatography (HPLC)
system has been described in detail elsewhere (Gibson et al.,
1993) and was applied to all the cell lines. Cells, at
-2-3 x 106ml-', were grown for the times indicated in
supplemented medium as described above for the cell culture.
MTX polyglutamation in L1210 cells was estimated using a
similar method and the polyglutamate standards were pur-
chased from Schircks Labs (Jona, Switzerland). Cells were
incubated with 0.5 gM [3HJMTX (sp. act.=19 Cimmol-')
for 24 h. Similarly, I gAM [benzoyl-3H]ICI 198583 (sp. act.
l9Cimmol[') was added to L1210 cells for 24h and ICI
198583 and its polyglutamates measured by reversed-phase
chromatography as previously described (Jackman et al., 1991c).
dUMP and 7TPpool measurements
L1210 or WIL2 cells (I0 ml in duplicate) at a ceUl density of
-2-3 x 10 ml-' were treated for 4h with ZD1694 at the
concentrations indicated. The cells were harvested by centri-
fugation and immediately extracted with cold perchloric acid
(PCA) (0.5 m). Similarly, flasks containing -3 x 106 non-
confluent 41M or CHI ovarian cells were treated with
ZD1694, washed once with PBS and PCA added directly to
the flask. The cells were detached from the flasks by scrapingAcqked resiskncr b DI
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and the extract transferred to conical test tubes. Following
neutralisation with potassium hydroxide (Curtin et al., 1991),
the ribonucleotides were destroyed using sodium periodate.
TTP pools were measured directly on aliquots of the extract
using a radioimmunoassay (RIA) (Aherne et al., 1993) sen-
sitive to -I pmol 10-6 cells. An RIA for dUTP (Piall et al.,
1989) was adapted to estimate 'immunoreactive' deoxyuridine
nucleotides (mainly dUMP) in the same cell extracts by
utilising the cross-reactivity of the antiserum to dUDP and
dUMP (Raynaud et al., 1993). The sensitivity of this assay
was also -I pmol 10-6 cells. All RIAs were performed in
duplicate at three dilutions of the extracts.
Cross-resistance studies
The quinazoline TS inhibitors were synthesised at Zeneca
Pharmaceuticals or the Institute ofCancer Research (Jones et
al., 1981; Hughes et al., 1990; Marsham et al., 1991, and in
preparation; Bavetsias et al., 1993; Boyle et al., in prepara-
tion). LY231514 and AG337 were synthesised at Zeneca
Pharmaceuticals. Lometrexol (DDATHF) was a gift from G
Grindey, Lilly Laboratories, Indianapolis, IN, USA and
BW1843U89 was a gift from R Ferone. Trimetrexate (TMQ)
was a gift from The National Cancer Institute (Bethesda,
MD, USA). Aminopterin, FdUrd and deoxythimidine (dThd)
were purchased from Sigma (London, UK) and MTX was
obtained from Nils Klass (Klausen, Denmark). Folinic acid
was supplied by David Bull Laboratories (Warwick, UK).
Cells were grown in the culture conditions described above
and IC,0 values determined as previously described (Jackman
et al., 1990). Each value was determined for at least five
dilutions (in duplicate) of each compound. Results are given
as the means ± s.d. of several experiments (three or more) or
as the individual results of one or two experiments.
Results
Development ofresistance
Although the four resistant cell lines were developed by
establishment in either 1 M (CHI and 41M) or 5M (L1210
and WIL2) ZD1694, the actual concentration to which they
were resistant varied considerably. The IC50 values for the
former lines were 0.36 and 1.7 JM respectively, while those of
the L1210 and W1L2 were >100uM.
Thymidylate svnthase activity andprotein level
Enzyme activity was similar for all four parental cell lines
and was significantly elevated in two of the resistant lines
(Table I). The 514-fold increase in TS activity in the
W1L2:RDl"' cells over the parental cells is, however,
significantly less than the >22 000-fold increase in IC50 for
ZD1694 observed, and similarly the 4.2-fold greater activity
in the CHl: RD694 cells is less than the 14-fold resistance to
the drug. An ELISA for TS indicated than an increase in the
TS protein was probably responsible for this raised TS
activity, although activity was at least twice the protein level
in each case. No change in dihydrofolate reductase activity
was found in any of the resistant cell lines (data not
shown).
Kinetic parametersfor TS isolatedfrom sensitive and resistant
CHI ovarian tumour cells
The inhibition of human ovarian CHl and CHI :RD16 TS by
ZD1694 and its triglutamate (the major metabolite in this cell
line) is mixed non-competitive with respect to (6R,S) 5,10-
CH2FH4. This is concluded from the fact that both K and
K;, could be determined (Table H). The relatively high values
of K. indicate that inhibition tends towards competitive, as
previously found using L1210 TS (Jackiman et al., 1991a).
The kinetic parameters were not significantly different for TS
isolated from the two cell lines. The K, values for ZD1694
were 91 and 85 nM for CHI and CHI:RDl' respectively and
similar to that reported for L1210 TS (60nM) (Jackman et
al., 1991a; Ward et al., 1992). The triglutamate of ZD1694
had a k. (1.6 nM) 57-fold lower than that of ZD1694 itself.
This enhancement in the K., was also demonstrated for the
tetraglutamate of ZD1694 using L1210 TS (Jackman et al.,
1991a; Ward et al., 1992).
dUMP and 7TPpool measurements
None of the four resistant cell lines had endogenous TTP
levels significantly different from their parental forms (Figure
1). When L1210:RDl" or WIL2:RDl" cells were either con-
tinuously subcultured (data not shown) or challenged for 4 h
(after 2 weeks in drug-free medium) with 5 gM ZD1694, 1TP
remained at the control level. The effect of ZD1694 on TIP
and deoxyuridine nucleotide pools ('dUMP') is also shown in
Figure 1. Perturbations in TTP and 'dUMP' pools occurred
in all four parental cell lines after exposure to ZD1694 at
appropriate doses. A 4 h exposure to 50gM ZD1694 reduced
TTP and increased 'dUMP' pools in L1210:RD16l cells by
only 15% and 12-fold respectively, indicating some inhibition
of TS. This compares with a 95% reduction in T-TP and a
26-fold increase in 'dUMP' with just 0.1 pM ZD1694 in the
parental line. Similarly, 'dUMP' and TIP levels were un-
affected in the WlL2:RD"' cells at 50gM drug, although in
the parental line 0.4gM reduced 1TP pools by 74% and
increased 'dUMP' 24-fold. These observations are consistent
with the > 100gM IC50 for the drug in these two resistant
lines. In 41M:RDIl" cells, both TIP and dUMP pools were
marginally affected by 0.1 and 1 FM drug exposure (IC50 =
Table I Kinetic parameters for TS isolated from the sensitive and
resistant human ovarian tumour CH1 cells
CHI TS CHI:RD165
K (6R,S) 5,10-CH2FH (LM) 24±0.8 22±0.8
K ZD1694 (nM) 91 ± 4.2 85± 6.1
K. ZD1694 (nM) 542± 23 440± 59
A ZD1694 triglu (nM) 1.6± 0.10 1.6± 0.12
K,, 7D1694 triglu (nM) 10 ± 0.70 9.1 ± 0.62
Table I Thymidylate synthase activity and TS protein level in ZD1694 sensitive and resistant cell lines
TS activits TS protein level
(nmoll-J cells h-'} Fold increase in (pmol 10-6 cells) Fold increase
Cell line Sensitive Resistant TS activity Sensitive Resistant in TS protein
CHI (human ovarian) 1.5 ± 0.66 6.3 ± 1.3 4.2* 0.24 0.51 2
0.089 0.19 2
41M (human ovanran) 2.0 0.64 2.5 0.49 1.3** 0.15 0.092 0.6
0.22 0.11 0.5
WIL2 (human lymphoblastoid) 1.6 0.33 820 200 514* 0.052, 0.012 5.7 178
0.089 16 180
L1210 (murine leukaemia) 1.4 ± 0.21 2.3 ± 0.91 1.6** 0.022, 0.023 0.014 0.5
0.040 0.08 2
TS activity was measured by 3H release from [5-3H`dUMP (mean ± s.d. of at least three experiments: *P<0.05; **not
significant) and TS protein levels by ELISA.Acquhe bsic ZDr1o
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Fugue 1 Deoxypyrimidinenucleotide pool measurements. After
extraction of the deoxynucleotides, 1TP was measured by RIA
using a specific antibody, and immunoreactive deoxyuridine
nucleotides (mainly dUMP) were measured by RIA using a
specific dUTP antibody that cross-reacts with dUMP and dUDP.
ITP and 'dUMP' levels in controls were -20 and 5 pmol 10-6
cells for the L1210 and WIL2 cells and -80 and lOpmol 10-6
cells for the CHI and 41M cells respectively.
1.7 jAM) compared with 60% and 80% reduction in TTP and
31- and 38-fold increase in dUMP in the parental line at
these doses. Pool size perturbations in the CHI and CHI:
RDIl lines were not so markedly different. ZD1694 at 0.1 pAM
for 4h caused T-P pools to fall by 81% and 58% in the
sensitive and resistant line respectively and by 88% in both
lines following 1 lJM ZD1694. IC5o values for growth inhibi-
tion of the resistant CHl line was 0.35 gAM ZD1694. 'dUMP'
pools mirrored the, changes in TITP pools.
Folylpolyglutamate synthetase activity
FPGS activity was determined in the L1210 cell lines using
D1694 as the substrate (3 JM). The activity in L1210 ceUs
was 2.0 ± 0.84 pmol h'- 10-6, whereas for the L1210:RD1694
cells it was only 0.25 ± 0.20 pmol h-' 10-6 cells. A similar
difference in activity was observed using MTX as the sub-
strate (data not shown).
Cellular transport/uptake studies
The 41M and L1210 sensitive and resistant lines were
incubated with 0.1 gM 2D1694 and the celular levels
measured up to 20 or 30min (Figure 2). Uptake of the drug
was significantly lower in both resistant lines compared with
the parental cells (-15-25%). Closer examination of the
L1210 parental cells revealed that within 15 min approx-
imately half of the intracellular drug was present as poly-
glutamates (data not shown). [3H]MTX transport was
therefore measured in these cells, the advantage being that
polyglutamate formation is relatively slow and no poly-
glutamates could be detected by 15 min (data not shown).
There was no significant change in the affinity (K) of MTX
for the RFC, but at least a 50% reduction in the V. was
observed (Table III). The K for ZD1694 as an inhibitor of
o
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Fugue 2 The uptake of 0.1 AM [(5H]ZD1694 into parental
(solid lnes) and resistant (dashed lines) mouse L1210 (circles) and
human ovarian 41M cells (squares). Cells were incubated in
unsupplemented RPMI-1640 (L1210) or Dulbecoo's modified
Eagle medium (41M) at 3TC.
Table Ji Kinetics for the transport ofmethotrexate into L1210 and
L1210:RD"'
V..." (pmollJ-6 Ki (Ium)
K, (JAM) cells mn-') D1694
L1210 4.2 0.3 1.6 + 0.07 2.4 0.1
4.0 0.2 0.93 0.14 2.6 0.2
L1210:RD"'I 3.8 ± 0.2 0.46 ± 0.02 3.7 ± 0.2
3.5 0.3 0.47 0.02 3.6 0.2
Cells were incubated in transport buffer with 0.5jiM [3H]MTX for
5 min in the presence ofvarying concentrations of MTX or ZD1694.
Each result (±s.e.) represents one experiment.
MTX transport was only marginally higher for the resistant
L1210 cells. This small alteration in the RFC is not sufficient
to explain the > 11 000-fold resistance to ZD1694. Further-
more, very little cross-resistance was seen to MTX, suggest-
ing that impaired transport is not a major determinant of
resistance (see Table VIII). However, the rate of transport of
[H]MTX into the 41M:RDl" cells was significantly reduced.
At an extracellular concentration of 0.5gM -0.6 pmol of
MTX had accumulated within 30mm in the 41M cells. This
was only 0.2 pmol in the 41M:RDlII cells (data not shown).
In addition, there was a concomitant 36-fold cross-resistance
to MTX (123-fold resistant to ZD1694) (see Table VII).
Further characterisation of the transport properties of these
41M cells was impaired by methodological problems with
this adherent cell line. Reproducible data could not be
obtained at short incubation times necessary to perform such
experiments. Changing the method to using single-cell
suspensions was not possible with this cell line as 'clumping'
occurred during the incubation.
Polyglutanation ofZD1694, MTXand ICI 198583
The total intracellular level of the drug in the 41M cells 24 h
after exposure to 0.1 gM [3H]ZD1694 was 8.8gM, i.e. 23-fold
higher than in the resistant 41M cells (Figure 3a). The levels
of the parent monoglutamate and its polyglutamate forms
were all reduced in the resistant cell line. However, the
predominant metabolite was the tnglutamate in both cell
lines. These data are consistent with a reduced rate of mem-
brane transport ofZD1694 in the resistant cells. The intracel-
lular pool of ZD1694 (particularly the triglutamate) could be
increased by raising the extracellular concentration to 1 FLM.
There was relatively more parent drug in the 4IM:RDl"
cells, which may indicate some reduction in the rate of
polyglutamate formation. The uptake of 0.1 FuM [3HZD1694
I
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over 24 h into L1210 cells resulted in a 38-fold higher intra-
cellular concentration of the drug, 98% of which was present
as polyglutamate forms (Figure 3b). However, in L1210:
RD1694 cells, the level was approximately equivalent to the
extracellular concentration and no polyglutamates were
found. Raising the extracellular level to 1 FLM resulted in
small, but detectable levels of polyglutamates. Resistance to
ZD1694 is clearly associated with a severely reduced ability
to form or maintain polyglutamates. To determine whether
this was a general effect on antifolates, [3H]MTX (0.5gM)
polyglutamation in the sensitive and resistant L1210 cell lines
was compared. Relative to ZD1694, MTX polyglutamation
was low in L1210 cells, with only -20% of total (5.3glM)
intracellular drug being found as polyglutamates at 24 h
(di-pentaglu). However, only parent drug (4.2gm) was seen
in the L1210:RDl" cells at the same dose (data not shown).
pHpICI 198583 (i gM) was well metabolised to polygluta-
mates in L1210 cells (total intracellular drug at 24h =
~-3jM; 75% as di-pentaglutamates, principally tetrag-
lutamate) (Jackman et al., 1991c). Again the L1210:RDIlM
cells were unable to form polyglutamates, with 98% of the
cellular 3H-labelled material (total = 2.6pzM) being identified
as parent drug (data not shown).
After 24 h exposure to 0.1SIM (3H]ZD1694, significant in-
tracellular accumulation was found in WlL2:RDl16 cells
(-3 x W1L2 parental line). Most was parent drug (28%) or
diglutamate (62%) (Figure 3c). In parental W1L2 cells only
1% and 2% of the drug was in these forms, the vast majority
being tetra- and pentaglutamates.
The TS-overproducing cell line, CHi:RDlR4, did not
accumulate a significantly higher level of ZD1694 when com-
pared with parental cells. However, there was, at 4 and 24h,
a shift to a greater proportion in the mono- to triglutamate
form in the resistant cells. The significance of this result is
difficult to interpret (Figure 3d).
Cross-resistance studies
The structures ofthe quinazoline TS inhibitors, together with
their TS inhibitory activity and FPGS substrate activity, are
given in Table IV. Results indicating their use of the RFC is
indicated in Tables V-VHI, and details can be found in the
following publications: Jack-man et al. (199la,c,d, 1993a,b),
Marsham et al. (1991), Boyle et al. (1993). Details of the
other compounds are described by Duch et al. (1993), Pav-
lovic (1993) and Webber et al. (1993).
WlL2:RDlW cells were highly cross-resistant to all quin-
azoline, pyrrolopyrimidine (LY231514) and benzoquinazoline
(BW1843U89) TS inhibitors, consistent with their high ex-
pression of TS (Table V). Lower cross-resistance was seen to
the lipophilic analogue, 10, which possibly relates to a second
locus of action becoming important to growth inhibition at
the higher compound concentration. No cross-resistance was
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Table IV Structures of quinazohne TS inhibitors
Inhibition of L1210 Mouse liver FPGS
RI R2 R3 Aryl R4 TS (IC50, AM) (K., pw)
1 (ZD1694) CH3 H CH3 Thiophene Glu 0.67 (K-=60 nM) a1.3
2 CH3 CH3 CH3 Thiophen Glu 0.11 b143
3 CH3 H CH3 Thiazole Glu 0.42 p0.91
4 (ICI 198583) CH3 H CH2CCH Benzene Glu 0.05 (1 = 10 nm) a43
5 (CB3717) NH2 H CH2CCH Benzene Glu 0.02 (K,=3nM) a40
6 CH3 CH3 CH2CCH Benzene Glu 0.028 bNon-sub
7 CH3 H H Benzene Glu 4.5 6.4
8 CH3 H CH2CCH Benzene Val 0.06 Non-sub
9 CH3 CH3 CH2CCH 2'F benzene L-Glu-t-D-Gu 0.00092 (4 =0.2 nM) Non-sub
10 CH3 CH3 CH2CCH Benzene meta-CN benzylamide 0.026 Non-sub
'Jackman et al. (1991d); bSanghani et al. (1994).
Tab V Activity of antifolates against W1L2 and W1L2:R ] D1694 human lymphoblastoid cells
Inhibition of WIL2 cell growth Resistance factor
LoCUs 'RFC FPGS S (IC50, 1w) R`*69 RIS
1 (ICI D1694) TS + + 0.0046±0.001 >100 (n=2) >22000*
2 TS + +/- 0.70, 0.76 >100 >140
3 TS + + 0.0029, 0.011 >100 14000
4 (ICI 198583) TS + + 0.058±0.0074 >100 (n=2) >1700*
5 (CB3717) TS - + 2.6 0.29 >100 (n=2) >38*
6 TS + - 0.15 0.047 >100 (n=2) >830*
7 TS + + 0.031 0.0023 >100 >3000
8 TS + - 0.42, 0.35 >100 >260
9 TS + - 0.17, 0.093 63 630
10 TS - - 0.068, 0.084 11, 18 190
LY231514 TS + + 0.029, 0.056 >100 (n=2) >2400
BW1843U89 TS + + 0.0023, 0.0022 3.4, 4.2 1700
AG337 TS - - 0.78 0.04 >10 >58
FdUrd TS - - 0.0054 0.0013 0.0078 ± 0.0069 1.4*
FdUrd+5 pm LV TS - + 0.0015 0.95 630
Trimetrexate DHFR - - 0.01, 0.018 0.023±0.021 1.3*
Methotrexate DHFR + + 0.0094±0.0018 0.0026, 0.0021 0.26*
Lometrexol GARTF + + 0.033 0.011 0.074, 0.045 1.8
'lDremin by inhibition of [3HJMTX tansport and/or activity against resistant cell lines with an impaired
RFC (Jackman et al., 1991acA 1993a,b; Marsham et al., 1991; Boyle et al., 1993; Duch et al., 1993; Pavlovic et
al., 1993; Webber et al., 1993). The signifiance of the difference between ICSO values for the S and R cells is:
*P<0.05; **Not significant.
Tab VI Activity of antifolates against human ovarian CHI and CHl:RD1'6" cells
Inhibon of CHlI cell growth Resistance factor
Compound LOCus RFC FPGS S (IC50, gm) R "4' RIS
(ICI D1694) T'S + + 0.025±0.011 0.36±0.12 14*
4 (IC 198583) T'S + + 0.34±0.17 4.7, 7.0 17*
5 (CB3717) TS - + 7.0± 1.8 55, 91 10*
6 T'S + - 7.9 ± 4.7 167 ± 97 21*
8 T'S + - 41 --.250 --7
9 T'S + - 1.3 ± 0.26 9.5 ± 3.9 7.3*
LY231514 T'S + + 3.0± 3.0 67± 2.9 22*
BW1843U89 TS + + 0.0012 ± 0.0006 0.0084 ±0.0025 7*
AG337 T'S - - 93 ± 1.2 22± 6.2 2.4*
FdUrd TS - - 0.044 ± 0.025 0.41 ± 0.23 9.3*
Trimetrexate DHFR - - 0.0086, 0.062 0.0073, 0.094 1.5
Methotrexate DHFR + + 0.017, 0.019 0.018, 0.0043 1.7
Lometrexol GARTF + + 0.42 ± 0.055 0.48 ± 0.2 1.1**
*P<0.05; **Not significant.
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Table Vl Activity of antifolates against human ovarian 41M and 41M:RD' ceUs
Inhibition of 41M cell growth Resistance factor
Locus RFC FPGS S (ICs, pm) RD104 R,S
1 (ICI D1694) TS + + 0.013±0.0043 1.7±0.63 123*
4 (ICI 198583) TS + + 0.13±0.06 5.3 2.9 41*
5 (CB3717) TS - + 5.6 2.7 7.6 4.5 1.4**
6 TS + - 21±15 131±56 9.9*
7 TS + + 0.19 0.02 8.8 4.9 46*
8 TS + - >50,-140 >100 -
9 TS + - 3.3±2.1 20±4.2 6.1*
LY231514 TS + + 0.22, 0.22 1.4, 2.0 7.7
BW1843U89 TS + + 0.0025 0.0007 0.66 ±0.065 264*
AG337 TS - - 6.7 ± 2.7 6.5 ± 3.1 0.97**
FdUrd TS - - 0.02 0.006 0.042 0.02 2.1**
Trimetrexate DHFR - - 0.082 0.068 0.015, 0.068 0.45**
Methotrexate DHFR + + 0.025 ± 0.015 0.69, 1.1 36
Lomotrexol GARTF + + 2.8 1.4 107, 100 37*
*P<0.05. **Not significant.
Table VIII Activity of antifolates against mouse L1210 and L1210:RD"' cells
Inhibition of L1210 cell growth
(IC50, LM) Resistance factor
Compound Locus ajFc FPGS S RDI64 (MB3) R/S
1 (ICI D1694) TS + + 0.0088±0.0031 >100 n=3 >11000*
2 TS + + - 1.6 0.3 9, 10 5.9*
3 TS + + 0.0060 0.0022 18, 15 3 000*
4 (ICI 198583) TS + + 0.15 0.036 2.7 0.47 18*
5 (CB3717) TS - + 5.0 1.2 13 ± 2.1 2.6*
6 TS + - 0.21 ± 0.036 0.56, 0.62 2.8*
7 TS + + 0.072±0.002 >100 n=2 >1400*
8 TS + - 1.1 0.51 3.7± 1.1 3.4*
9 TS + - 0.2±0.017 0.3, 0.52 2
10 TS - - 0.89 0.19 0.35 ± 0.18 0.4*
LY231514 TS + + 0.034 0.006 3.9, 5.1 132
BW1843U89 TS + + 0.086 0.045 0.36, 0.43 4.7*
AG337 TS - - 0.70 0.04 1.4, 1.2 1.8
FdUrd TS - - 0.0023 ± 0.001 0.0035 ± 0.0016 1.5**
Trimetrexate DHFR - - 0.018 ± 0.0076 0.016 ± 0.0087 0.89**
Methotrexate DHFR + + 0.011 ±0.0035 0.024 ± 0.003 2.2*
Aminopterin DHFR + + 0.0024, 0.0024 0.0075, 0.004 2.4
Lomotrexol GARTF + + 0.11 ± 0.041 2.3 ± 0.41 21*
*P<0.05; **Not significant.
observed to the pyrimidine-based TS inhibitor 5-fluorode-
oxyuridine (FdUrd) unless folinic acid (leucovorin, LV) was
given. The addition of dThd (as well as LV) rendered FdUrd
poorly active in either cell line (IC50 -65gM). Inhibitors of
DHFR (MTX and trimetrexate) and glycinamide ribotide
transformylase (GARTF) (Lometrexol) retained activity in
the ZD1694-resistant WlL2 cells.
Lower levels of resistance to ZD1694 and other TS
inhibitors, including FdUrd, were seen in the CH1:RDII
cells (2- to 22-fold) (Table VI). The 2.4 cross-resistance to
AG337 may relate to its poor activity against the parental
line (9.3 tIM) with the possibility of another locus becoming
significant at the higher concentration used against the resis-
tant cells. No significant cross-resistance was seen to inhib-
itors of other folate-dependent enzymes, e.g. MTX, trime-
trexate or Lometrexol.
The pattern of cross-resistance to the antifolates was very
different in the other two cell lines, and the results are crucial
in explaining the mechanisms of resistance involved. This is
because the data separating transport from an FPGS defect
were not definitive (see above). The 41M:R D1694 cells were
only cross-resistant to compounds (whatever the target
enzyme) known to use the RFC, although the degree of
cross-resistance varied widely (6- to 264-fold) (Table VII).
The L1210:RDl9 cell line produced cross-resistance results
that can all be explained as a consequence of defective poly-
glutamation (Table VIII). High cross-resistance was observed
to the thiazole derivative of ZD1694 (3) and to 7, both very
good FPGS substrates (K.= 1.0 and 6.4liM respectively)
(Jack-man et al., 1991d). The degree of cross-resistance to
other analogues was lower, and was again consistent with
their reduced potential to form intracellular polyglutamates.
Thus, ICI 198583 with a relatively high K. for FPGS (40gM)
is less extensively polyglutamated in L1210 cells than ZD1694
(Jackman et al., 1991c). No significant cross-resistance was
seen to all antifolates known to be non-substrates for FPGS
and that do not use the RFC, i.e. 10, AG337 and trnmetrex-
ate. Similarly no cross-resistance was observed to FdUrd.
Non-polyglutamatable compounds that use the RFC (e.g. 6,
8 and 9 and other unpublished examples) have cross-resis-
tance values (2-3) significantly greater than 1, consistent
with the small transport defect in the resistant line described
above. A very low level of cross-resistance was observed to
CB3717, MTX and aminopterin (2- to 3-fold). However a
higher level ofresistance (15-fold) was demonstrated to MTX
if the drug exposure period was limited to 6h (data not
shown). Indirect evidence supports polyglutamation of
natural folates occumng normally in the L1210:RDl" cells.
The addition of 5 jAM leucovorin to cell cultures containing
FdUrd resulted in a significant enhancement in growth
inhibition (-2.5-fold) in both lines (data not shown). This is
a well-recognised synergistic combination since stable ternary
complex formation is promoted by elevating the 5,10-
CH2FH4 pool with leucovorin. Similarly, when leucovorin
(5pM) was used to protect against the activity of the DHFR
inhibitor, trimetrexate, both sensitive and resistant L1210
cells were protected to the same degree (-20-fold increase in
IC"). Since leucovorin is metabolised to natural folate poly-
glutamates, this provides circumstantial evidence for normal
folate polyglutamation in L1210:R"'69' cells.Acquired resistance to ZD1694
AL Jackman et al
Discussion
Continuous exposure of four cell lines to incremental in-
creases in the concentration of ZD1694 led to each line
acquiring at least one of three mechanisms of resistance: TS
overproduction, alteration in the RFC or defective poly-
glutamation. There was always one primary mechanism of
resistance, although a second mechanism (either independent
or a consequence of the first) was also observed in each cell
line.
Although the cell lines were adapted to grow in 1-S5JM
ZD1694, two of the resistant cell lines (WIL2 and L1210)
were highly resistant, even -when challenged with 100 1M
ZD1694. Consistent with TS inhibition, all parental cells had
depletion of TTP and elevation of 'dUMP' pools following
incubation for 4 h with growth-inhibitory concentrations of
ZD1694. These pools were either not, or minimally, disturbed
when L1210 or W1L2 resistant cells were exposed to 50JM
ZD1694, demonstrating that TS operates relatively normally
under these conditions. This would be expected from the high
level of resistance described above. The two resistant ovarian
lines, particularly the CH1:RD1694 line, showed disturbances
in pool size at much lower concentrations consistent with
their lower levels of resistance.
Two of the human cell lines, Wl L2 and CH1, had
significantly elevated TS activity (500- and 4-fold respec-
tively). TS protein levels were similarly increased when deter-
mined by ELISA (Table I). Immunoblotting demonstrated a
similar increase, and this was accompanied by a 100- and 2-
to 3-fold increase in TS gene copy number and mRNA
respectively (Freemantle et al., 1993). The human ovarian cell
line, CHI, has a low level (14-fold) of ZD1694 resistance,
and here the resistance is generally consistent with the small
elevation in TS activity (levels). No change in the TS inhibi-
tion kinetic parameters (ZD1694 or its triglutamate) was
observed. As expected, cross-resistance was seen to all TS
inhibitors, including FdUrd, but not to inhibitors of DHFR
(MTX or trimetrexate) or GARTF (Lometrexol). Mechanism
of cellular uptake was not a factor that correlated with
cross-resistance, and indeed intracellular ZD1694 levels were
not significantly different in the sensitive and resistant cells.
However at 24 h, a consistent shift in the distribution of the
polyglutamate forms to shorter chain length was apparent in
the resistant line, which may contribute to the resistance
seen.
The human W1L2 resistant cell line was highly resistant to
ZD1694 (ICs >100gM) even though it had been adapted to
grow in just 5 JAM drug. Contrary to what we expected, the
resistant cells accumulated significantly higher levels of intra-
cellular drug than the'sensitive cells. However, the majority
was present as either the parent drug or diglutamate, and this
is most readily explained by the 500-fold increased level of
TS protein. The high level ofTS may reduce 'free' drug levels
by binding the mono- to triglutamate, preventing the addi-
tion of further glutamate residues by FPGS. The relatively
weaker binding to TS of the mono- and diglutamate com-
pared with the higher polyglutamates must allow polygluta-
mation to proceed as far as the triglutamate, but the slower
dissociation of this form from TS may prevent further poly-
glutamate chain elongation by reducing substrate availability.
This phenomenon has also been observed in another TS-
overproducing line (WlL2:Cl) with resistance to ICI 198583.
Here there was a 30-fold higher intracellular concentration of
drug with 97% in the monoglutamate form compared with
9% in the parental cells (O'Connor et al., 1992). The lower
level of cross-resistance to quinazoline TS inhibitors that are
not substrates for FPGS, e.g. 9 and 10, is therefore expected.
Sensitivity to the DHFR inhibitors (MTX and trimetrexate)
and the GARTF inhibitor (Lometrexol) is completely consis-
tent with TS overproduction being the only alteration in the
WIL2:RD1694 cells. Sensitivity to FdUrd is explained by
sequestration of the 5,10-CH2FH4 pool into the ternary com-
plex with TS (in large excess) and FdUMP, resulting in
inhibition ofTS and other folate-dependent enzymes through
substrate depletion. This is why supplying the cell with folinic
acid, which reinstates de novo purine and TMP synthesis by
replenishment of the reduced folate pool, allows resistance to
FdUrd to be revealed. We have previously recorded this
phenomenon in other cell lines with amplified TS genes
(Jackman et al., 1986; O'Connor et al., 1992).
Gene amplification leading to increased TS expression as a
mechanism of experimental resistance to pyrimidine-based
(FdUrd) (Baskin et al., 1975; Priest et al., 1980; Rossana et
al., 1982; Berger et al., 1985; Jenh et al., 1985) or folate-
based TS inhibitors has been previously reported (Jackman et
al., 1986; Iman et al., 1987; Danenberg and Danenberg, 1989;
O'Connor et al., 1992). There is also evidence that this can
occur in man in response to treatment with 5-FU (Clark et
al., 1987). The introduction of new antifolates, targeted
towards TS, into the clinic may establish whether this will be
a common resistance mechanism in man.
The second human ovarian 41M line (-100-fold resistant
to ZD1694) appears to have a primary defect, which is
reduced drug uptake via the RFC. A consequence of lower
intracellular level of the parent drug is a substantially
reduced concentration of the more active intracellular poly-
glutamates. Thus, the cross-resistance seen to antifolates
known to use the RFC, including those with targets other
than TS, was expected. CB3717 uses this carrier poorly (as
determined in L1210 cells) (Jackman et al., 1990, 1993a),
while the lipophilic compounds AG337 (Webber et al., 1993)
and trimetrexate (Fry and Jackson, 1986) do not use it at all,
and of course FdUrd uses a nucleoside transport mechanism.
All of these compounds retained activity in the resistant cells.
The very high cross-resistance seen to BW1843U89 may
relate to the excellent affinity this compound has for the
human RFC (Duch et al., 1993). Transport defects have
frequently been reported as a mechanism of resistance to
MTX (Fry and Jackson, 1986). Defective transport is also
commonly associated with other resistance mechanisms, in-
cluding a reduced ability to form or maintain polyglutamates
of MTX or Lometrexol (Cowan and Jolivet, 1984; Assaraf et
al., 1992; Koizumi and Allegra, 1992; Rhee et al., 1993).
The importance of polyglutamation in the action of anti-
folates such as MTX and Lometrexol has led to the recent
description of several cell lines with intrinsic or acquired
resistance due to a reduced accumulation of polyglutamate
species (Pizzorno et al., 1988, 1989; McCloskey et al., 1991;
Van der Laan et al., 1991; Li et al., 1993; Pavlovic et al.,
1993). Considering the importance of polyglutamate forma-
tion for the cytotoxicity of ZD1694 (Jackman et al., 1991a,
1993a), it is not surprising that one of our cell lines,
Ll210:RDl', proved to be defective in this manner. The
greatly reduced ability to form (or maintain) intracellular
ZD1694 polyglutamates in this resistant line also extends to
ICI 198583 and MTX as determined by radiolabelled drug
studies. This reduction in polyglutamation potential is most
likely accounted for by the '90% reduction in FPGS
activity (using MTX or ZD1694 as substrates). Deletion of
FPGS has been shown to be a lethal mutation (McBurney
and Whitmore, 1974), but reports of lower expression of
FPGS or altered activity for antifolates (MTX and Lome-
trexol) has been described (Pizzorno et al., 1988; McCloskey
et al., 1991; Pavlovic et al., 1993). It has also been shown
that decreased FPGS activity does not necessarily reduce the
ability of the cell to polyglutamate sufficient natural folates
for normal cellular function (Pizzorno et al., 1988; Pavlovic
et al., 1993). In other cell lines with decreased ability to
polyglutamate MTX the actual mechanisms have not been
fully elucidated (Pizzorno et al., 1988, 1989; Assaraf et al.,
1992). Increased 'y-glutamylhydrolase activity as a mechanism
of antifolate resistance is increasingly being reported (Li et
al., 1993; Rhee et al., 1993). However, in studies not reported
here, this activity was barely detectable in both sensitive and
resistant L1210 cells and is therefore unlikely to be a contri-
butory factor. The very low activity of y-glutamylhydrolase
in L1210 cells grown in vitro, as opposed to in mice, has been
described by Samuels et al. (1986). Thus, this enzyme may
play a greater role in maintaining polyglutamate homeostasis
in mice and may be important in differential tissue sensitivity
921
0
0qukdD acc ZD 1U
AL Jackman et a
922
to ZD1694, and its elevation could be a potential resistance
mechanism.
The results of the cross-resistance studies support a poly-
glutamation defect, as only TS inhibitors, active through
polyglutamation, had significantly reduced activity against
the L1210 resistant cells. Some apparent anomalies do exist
but can be explained including the low level of cross-
resistance to CB3717 (3-fold) or to the pteridine-based
DHFR inhibitors, MTX and aminopterin (2- to 3-fold).
CB3717 does form polyglutamates in L1210 cells, but rela-
tively slowly. For example, after incubation with equitoxic
concentrations of ZD1694 (0.1 gM) and CB3717 (50gM) for
4 or 6 h respectively, 98% of D1694 and only 15% of
CB3717 was measured as polyglutamates (Sikora et al., 1988;
Jackman et al., 1991a). CB3717's lower dependence on polyg-
lutamate formation for activity, in addition to the slightly
lower cross-resistance expected from a compound that does
not use the RFC (small transport defect, see above), prob
ably explains the low cross-resistance observed. A lower
requirement for polyglutamation may partially explain the
good activity of MTX and aminopterin in the resistant cells
(MTX is poorly polyglutamated at low intracellular concent-
rations). Furthermore, the polyglutamates of DHFR
inhibitors, unlike the quinazoline TS inhibitors, are not
significantly more potent as inhibitors of their target enzyme
(Szeto et al., 1979; Chabner et al., 1985) than the parent
monoglutamate, and the importance oftheir formation lies in
their drug retentive properties (Galivan, 1980; Jolivet and
Chabner, 1983). Thus, under continuous drug exposure con-
ditions, the lack of polyglutamate formation is not partic-
ularly deleterious, however under short exposure conditions
(6 h), when drug retention is important, MTX was -15-fold
less active in the resistant than in the L1210 parental line.
Similarly, the TS inhibitor BW1843U89 has similar activity
against TS in either the parent monoglutamate or dig-
lutamate form (Duch et al., 1993) and may therefore account
for the low level of cross-resistance to this agent.
The acquisition of these four ZD1694-resistant cell lines
has confirmed the importance ofTS, the RFC and polygluta-
mation for the activity of the drug. Clearly, it is likely that
certain tumours may intrinsically possess or acquire these
phenotypes. However, as more antifolates are developed for
clinical study with differing target enzymes, transport and
metabolic properties, it will be possible to overcome these
resistance mechanisms. This panel of resistant cell lines has
aided the development of quinazoline TS inhibitors that are
not metabolised by FPGS but still require cellular uptake via
the RFC and are currently being used to identify compounds
whose activity is independent of either process.
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